Jon Christopher Stringer, MD
Internal Medicine · Manlius, NYNPI 1306827142
Payments from drug & device makers
Across 251 payments — averaging $3193.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$607K
- Biohaven Pharmaceuticals, Inc.$117K
- Janssen Research & Development, LLC$38K
- Biohaven Pharmaceutical Holding Company Ltd.$23K
- Eli Lilly$13K
- Merck$2K
- plus $2K from 20 others
Across 1 payment — averaging $212.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$212
What the payments were for
- Travel & lodging$1,17633%
- Food & beverage$2,41567%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $606,690 |
| Biohaven Pharmaceuticals, Inc. | 21 | $117,476 |
| Janssen Research & Development, LLC | 12 | $38,343 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $22,601 |
| Eli Lilly | 5 | $12,950 |
| Merck | 17 | $1,627 |
| Lilly USA, LLC | 16 | $243 |
| Boehringer Ingelheim | 12 | $186 |
| Novo Nordisk | 12 | $183 |
| Amgen(2 entities) | 11 | $180 |
| Pfizer | 15 | $180 |
| Astellas Pharma US Inc | 8 | $146 |
| Amarin Pharma, Inc. | 9 | $133 |
| Novartis | 7 | $104 |
| GSK | 6 | $90 |
| AstraZeneca | 5 | $72 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $51 |
| Exact Sciences | 2 | $35 |
| IBSA Pharma Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
How this compares
$801,495 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $98,934 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $54,181 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $45,030 |
| JardianceEmpagliflozin | 37 | $42,076 |
| XareltoRivaroxaban | 41 | $38,816 |
| OzempicSemaglutide | 27 | $33,024 |
| JanuviaSitagliptin Phosphate | 33 | $31,624 |
| MyrbetriqMirabegron | 37 | $20,092 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $18,596 |
| TradjentaLinagliptin | 13 | $18,315 |
| EntrestoSacubitril/Valsartan | 18 | $17,443 |
| MounjaroTirzepatide | 14 | $16,849 |
| InvokanaCanagliflozin | 14 | $10,652 |
| EdarbiAzilsartan Medoxomil | 20 | $9,969 |
| Praluent PenAlirocumab | 13 | $6,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $180 | $98,93489 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $90 | $67,43167 claims |
| Boehringer IngelheimJardiance, Tradjenta | $186 | $60,39250 claims |
| Johnson & JohnsonXarelto, Invokana | $29 | $49,46855 claims |
| Novo NordiskOzempic | $183 | $33,02427 claims |
| MerckJanuvia | $1,627 | $31,62433 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $20,09237 claims |
| NovartisEntresto | $104 | $17,44318 claims |
| Lilly USA, LLCMounjaro | $243 | $16,84914 claims |
| AbbVieSynthroid | $606,690 | $1,45728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Manlius
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.